HHC
IBB icon

Hutchin Hill Capital’s iShares Biotechnology ETF IBB Stock Holding History

Hutchin Hill Capital’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-90,000
Closed -$7.96M – 945
2016
Q4 		$7.96M Buy
+90,000
New +$8.19M 0.28% 79

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hutchin Hill Capital's IBB Position: Q1 2017 in Review

Hutchin Hill Capital sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 16,500 shares — an estimated $1.46M sold.

Hutchin Hill Capital first reported a position in IBB in Q3 2014 and held it in 2 quarters. The position peaked at $1.46M in Q4 2016. 521 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

  • Hutchin Hill Capital reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 16,500 iShares Biotechnology ETF shares in Q1 2017, an estimated $1.46M.
  • Hutchin Hill Capital first reported a position in iShares Biotechnology ETF in Q3 2014 and held it in 2 quarters.
  • Hutchin Hill Capital's iShares Biotechnology ETF position peaked at $1.46M in Q4 2016.
  • 521 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on Hutchin Hill Capital's 13F filing for Q1 2017, filed 15 May 2017.